Literature DB >> 12000063

Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease.

W E Hopkins1, N K Fukagawa, B E Sobel, D J Schneider.   

Abstract

In the present study we have shown that adults with Down syndrome have reduced plasminogen activator inhibitor type-1 in blood compared with control subjects matched for age, gender, and body mass. Reduced plasminogen activator inhibitor type-1 may explain the low incidence of atherosclerotic vascular disease and its complications that are attributable to plaque instability, such as myocardial infarction and unstable angina, in subjects with Down syndrome, despite an ever-increasing life expectancy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12000063     DOI: 10.1016/s0002-9149(99)00864-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Cardiovascular Prevention Among Young Adults with Congenital Heart Disease.

Authors:  Matthew R Lippmann; Ami B Bhatt
Journal:  Curr Atheroscler Rep       Date:  2022-04-30       Impact factor: 5.967

Review 2.  Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management.

Authors:  Angela E Lin; Craig T Basson; Elizabeth Goldmuntz; Pilar L Magoulas; Deborah A McDermott; Donna M McDonald-McGinn; Elspeth McPherson; Colleen A Morris; Jacqueline Noonan; Catherine Nowak; Mary Ella Pierpont; Reed E Pyeritz; Alan F Rope; Elaine Zackai; Barbara R Pober
Journal:  Genet Med       Date:  2008-07       Impact factor: 8.822

3.  Atherosclerotic Surrogate Markers in Adults With Down Syndrome: A Case-Control Study.

Authors:  Pedro Parra; Ramón Costa; Diego Real de Asúa; Fernando Moldenhauer; Carmen Suárez
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-06       Impact factor: 3.738

4.  NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect.

Authors:  Georgios C Stefos; Ulf Soppa; Mara Dierssen; Walter Becker
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

Review 5.  Adults with Down syndrome challenge another paradigm: When aging no longer entails arterial hypertension.

Authors:  Emilia Roy-Vallejo; José María Galván-Román; Fernando Moldenhauer; Diego Real de Asúa
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-09       Impact factor: 3.738

6.  Maternal plasma angiogenic and inflammatory factor profiling in foetal Down syndrome.

Authors:  Monika Zbucka-Kretowska; Karol Charkiewicz; Joanna Goscik; Slawomir Wolczynski; Piotr Laudanski
Journal:  PLoS One       Date:  2017-12-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.